Interferon-alpha-n3 - Hemispherx Biopharma

Drug Profile

Interferon-alpha-n3 - Hemispherx Biopharma

Alternative Names: Alferon LDO; Alferon LDO (Low Dose Oral); Alferon N; Alferon N Gel; Alferon N Injection; Alferon N LDO; alpha-n3-IF; Altemol; Interferon alfa-N3; Interferon alfa-n3 human leukocyte derived (Alferon N Injection); Interferon-α-n3; Leukocyte interferon; Naturaferon; Natural alpha interferon

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stem Cell Innovations
  • Developer Fujimoto Pharmaceutical; Hemispherx Biopharma; Howard University; National Institute of Allergy and Infectious Diseases; Swiss Department of Defence, Civil Protection and Sport; United States Army Medical Research Institute of Infectious Diseases
  • Class Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Middle East respiratory syndrome coronavirus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Human papillomavirus infections
  • Registered Hepatitis C; Inflammation; Multiple sclerosis; Viral infections
  • Preclinical Zika virus infection
  • Research Ebola virus infections
  • No development reported HIV infections; Influenza A virus H7N9 subtype; Influenza A virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Venezuelan equine encephalomyelitis; West Nile virus infections
  • Discontinued Kaposi's sarcoma; Small cell lung cancer

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype in Switzerland (SC)
  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-virus-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top